🔗 Share this article

While the US continues making unprecedented changes to its immunization guidelines, a particular individual has emerged in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on coronavirus vaccinations in the pandemic and has zeroed in on potential fatalities after Covid vaccination in her short time at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Program

Agency leaders were set to announce sweeping changes to the pediatric immunization program recently, aligning the US with Denmark’s national calendar, it is understood – a major change that would put the US out of alignment with a large portion of the global community with insufficient data for public health gain. The announcement has been pushed back until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the event. She was newly appointed interim head of the FDA’s CDER, the fifth person to run the office this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting specific pediatric vaccine recommendations in the US to become more similar to the Danish model, a nation with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has little discernible background in drug development, oversight or leadership, which has been typical for former leaders of the CBER. She has been employed at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a major agency. She has no expertise in drug approvals.”

Past commissioners of CBER would “understand legal statutes and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who ran CBER have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“Everybody just pays attention on the novel medication approvals, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and each of these must be supervised,” she noted. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major administrative aspect to the role, which oversees in excess of 5,000 staff members. “It is a huge management job, if you execute it properly,” the former official concluded.

Official Statement and Contentious Policies

In response to questions about Høeg’s credentials and whether this appointment represents increased cooperation among FDA leaders on vaccines, a press secretary stated that the “questions stem from inaccurate premises”.

“This background matches the responsibilities of her position,” the official explained, citing the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed one-day therapy clearance system that allegedly troubled her predecessors. “By what process are these therapies being selected for this expedited pathway? Who is making the choices?” Howard said. “There is a lot of confidentiality going on at the FDA right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent regulations of most medications, except for shots.”

Documented Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if concerning, history, some experts said. She authored a research paper using unverified volunteer-provided data to assess the incidence of myocarditis after Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are more dangerous than they are.

Among her “desired changes” for the new government encompassed revising regulations for novel immunizations and halting “non-essential” immunizations, she stated post-election on a online show. At the FDA, Høeg has according to sources floated the idea of excluding young men from obtaining Covid vaccines.

“She is an thorough dogmatist who begins with her preconceived notions and tailors the evidence to retrofit the science in a highly misleading, fraudulent manner,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|